JP2023540611A5 - - Google Patents

Info

Publication number
JP2023540611A5
JP2023540611A5 JP2023515803A JP2023515803A JP2023540611A5 JP 2023540611 A5 JP2023540611 A5 JP 2023540611A5 JP 2023515803 A JP2023515803 A JP 2023515803A JP 2023515803 A JP2023515803 A JP 2023515803A JP 2023540611 A5 JP2023540611 A5 JP 2023540611A5
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540611A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/075005 external-priority patent/WO2022053650A1/en
Publication of JP2023540611A publication Critical patent/JP2023540611A/ja
Publication of JP2023540611A5 publication Critical patent/JP2023540611A5/ja
Pending legal-status Critical Current

Links

JP2023515803A 2020-09-11 2021-09-10 治療用b7-h4結合分子 Pending JP2023540611A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063077207P 2020-09-11 2020-09-11
US63/077,207 2020-09-11
PCT/EP2021/075005 WO2022053650A1 (en) 2020-09-11 2021-09-10 Therapeutic b7-h4 binding molecules

Publications (2)

Publication Number Publication Date
JP2023540611A JP2023540611A (ja) 2023-09-25
JP2023540611A5 true JP2023540611A5 (cg-RX-API-DMAC7.html) 2024-09-09

Family

ID=77989768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515803A Pending JP2023540611A (ja) 2020-09-11 2021-09-10 治療用b7-h4結合分子

Country Status (17)

Country Link
US (2) US11795225B2 (cg-RX-API-DMAC7.html)
EP (1) EP4211166A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023540611A (cg-RX-API-DMAC7.html)
KR (1) KR20230084497A (cg-RX-API-DMAC7.html)
CN (1) CN116829592A (cg-RX-API-DMAC7.html)
AR (1) AR123480A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021339953B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023004415A2 (cg-RX-API-DMAC7.html)
CA (1) CA3193594A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000683A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023004379A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230146A (cg-RX-API-DMAC7.html)
EC (1) ECSP23025680A (cg-RX-API-DMAC7.html)
IL (1) IL301041A (cg-RX-API-DMAC7.html)
MX (1) MX2023002940A (cg-RX-API-DMAC7.html)
SA (1) SA523442921B1 (cg-RX-API-DMAC7.html)
WO (1) WO2022053650A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202140076A (zh) * 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
CN115160403B (zh) * 2022-07-05 2025-06-27 博石丰生命科技(南通)有限公司 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法
EP4309676A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
CA3263276A1 (en) * 2022-07-28 2024-02-01 Medimmune, Llc Polytherapy for the treatment of cancer
KR20250079213A (ko) 2022-10-09 2025-06-04 라노바 메디신즈 리미티드 화합물, 조성물 및 방법
TW202448517A (zh) * 2023-02-16 2024-12-16 瑞典商阿斯特捷利康公司 用治療性結合分子治療癌症的組合療法
EP4701665A1 (en) * 2023-04-28 2026-03-04 MedImmune Limited B7-h4 therapeutic binding molecules for the treatment of cancer
KR20260048598A (ko) * 2023-07-31 2026-04-10 아스트라제네카 아베 Cd123 항체-약물 접합체 및 이의 사용 방법
AU2024380559A1 (en) 2023-11-17 2026-06-04 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2026151884A1 (en) 2025-01-09 2026-07-16 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US776841A (en) 1904-03-16 1904-12-06 Annie L See Piano-action.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3587814T2 (de) 1985-03-30 1994-11-10 Marc Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
EP1521769B1 (de) 2002-07-09 2015-09-09 Dömling, Alexander Tubulysinkonjugate
US7816377B2 (en) 2002-07-09 2010-10-19 R&D-Biopharmaceuticals Gmbh Tubulysin analogues
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
WO2006121207A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
US8476451B2 (en) 2007-07-20 2013-07-02 The Regents Of The University Of California Tubulysin D analogues
EP2181101A2 (en) 2007-07-20 2010-05-05 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
EP2209374B1 (en) 2007-10-25 2014-12-03 Endocyte, Inc. Tubulysins and processes for preparing
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
US8889880B2 (en) 2010-08-06 2014-11-18 Endocyte, Inc. Processes for preparing tubulysins
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
CA2943299A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
WO2015155345A1 (en) 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
CA2945318A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Tubulysin derivatives
TW201625689A (zh) * 2014-09-12 2016-07-16 建南德克公司 抗-b7-h4抗體及免疫結合物
US10626176B2 (en) * 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
AR113102A1 (es) * 2017-08-25 2020-01-29 Five Prime Therapeutics Inc Anticuerpos anti b7-h4 y métodos de uso de los mismos
WO2020140070A1 (en) * 2018-12-27 2020-07-02 Gigagen, Inc. Anti-b7-h4 binding proteins and methods of use thereof
MX2023000662A (es) * 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.

Similar Documents

Publication Publication Date Title
JP7401126B2 (ja) 抗cubドメイン含有タンパク質1(cdcp1)抗体、抗体薬物コンジュゲート、およびその使用方法
ES2657970T3 (es) Anticuerpos contra ROR1 de conejo/ser humano quiméricos
CN110121507B (zh) 抗sez6l2抗体和抗体药物缀合物
JP2018127469A5 (cg-RX-API-DMAC7.html)
KR20210042120A (ko) 항체-약물 콘주게이트와 튜불린 저해제의 조합
KR20200027971A (ko) 항-cd166 항체 및 이의 용도
JP2017535246A5 (cg-RX-API-DMAC7.html)
CN113784987B (zh) 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
JP2019532056A5 (cg-RX-API-DMAC7.html)
AU2016203839A1 (en) Antibody-drug conjugates
JP2014524902A5 (cg-RX-API-DMAC7.html)
CN113710271A (zh) 抗cd228抗体和抗体-药物缀合物
US20230167200A1 (en) Platform for constructing multispecific antibody
JP2022016581A (ja) 抗edb抗体および抗体-薬物コンジュゲート
JP7264831B2 (ja) 抗globo h抗体を含有する抗体-薬物コンジュゲートおよびその使用
JP2022512139A (ja) 腫瘍性疾患の治療のためのpd-l1抗体と組み合わせたil-15タンパク質複合体の使用
JP7679380B2 (ja) Cd276に特異的な抗体-薬物コンジュゲートおよびその使用
JP7379347B2 (ja) プレクチン1結合抗体およびその使用
AU2018285523A1 (en) Antibody drug conjugates that bind LGR5
JP2025508380A5 (cg-RX-API-DMAC7.html)
US20240358847A1 (en) Trop2 binders and conjugates thereof
CN110141666A (zh) 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途
WO2025099152A1 (en) Antibodies and molecular conjugates thereof targeting upar
TW202444431A (zh) 抗體藥物偶聯物在製備預防和/或治療癌症的藥物中的用途
WO2026098621A1 (zh) 工程改造的定点偶联抗体、抗体偶联药物及其应用